SCHEMBL3971418

SCHEMBL3971418

CCN(CC)CCCNc1ncc2c(n1)NC(=O)N(c1cc(OC)cc(OC)c1)C2

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR4 P22455 9/20 0.52
FGFR1 P11362 11/20 0.42
FGFR2 P21802 8/20 0.42
FGFR3 P22607 7/20 0.42
KDR P35968 5/20 0.42
FLT1 P17948 3/20 0.42
FLT4 P35916 3/20 0.42
SRC P12931 2/20 0.41
GLA P06280 1/20 0.41
CSK P41240 1/20 0.41
KMT2A Q03164 1/20 0.41
ATM Q13315 1/20 0.41
HSP90AA1 P07900 1/20 0.41
HSP90AB1 P08238 1/20 0.41
EGFR P00533 1/20 0.40
CCR4 P51679 2/20 0.40
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
HPGD P15428 1/20 0.39
HSD17B10 Q99714 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3971289 0.97 FGFR4 (0.51) FGFR4FGFR1FGFR2FGFR3KDR
SCHEMBL3972885 0.84 FGFR4 (0.47) FGFR4FGFR1FGFR2FGFR3KDR
SCHEMBL3979713 0.84 FGFR4 (0.52) FGFR4FGFR1FGFR2FGFR3KDR
SCHEMBL3974703 0.83 FGFR4 (0.51) FGFR4FGFR1FGFR2FGFR3KDR
SCHEMBL3967389 0.82 LCK (0.54) FGFR4FGFR1FGFR2FGFR3KDR
SCHEMBL3969621 0.82 FGFR4 (0.51) FGFR4FGFR1FGFR2FGFR3KDR
SCHEMBL3972876 0.82 FGFR4 (0.49) FGFR4FGFR1FGFR2FGFR3KDR
SCHEMBL3969871 0.80 FGFR4 (0.52) FGFR4FGFR1FGFR2FGFR3KDR
SCHEMBL3971372 0.79 FGFR4 (0.51) FGFR4FGFR1FGFR2FGFR3KDR
SCHEMBL3968941 0.76 FGFR4 (0.51) FGFR4FGFR1FGFR2FGFR3KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7501425-B1 Bicyclic pyrimidines and bicyclic 3,4-dihydropyprimidines as inhibitors of cellular proliferation WARNER LAMBERT COMPANY (US) 2009-03-10 US disclosed
EP-1080092-B1 BICYCLIC PYRIMIDINES AND BICYCLIC 3,4-DIHYDROPYRIMIDINES AS INHIBITORS OF CELLULAR PROLIFERATION WARNER LAMBERT CO (US) 2008-07-23 EP disclosed
EP-1801112-A1 Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation Warner-Lambert Company LLC (US) 2007-06-27 EP disclosed
US-20040044012-A1 Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation DOBRUSIN ELLEN MYRA (US) 2004-03-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040044012-A1 Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation CCNI, CCNH, CCNA1 FGFR4 95/4885FGFR1 55/4885FGFR2 93/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.